DiaPlus Clinics - Diabetes Specialists
 
 
 
 
 
 
 
 
 For Appointments: click here
 
   Home      Sitagliptan
 
DIABETES
 
DIABETES MELLITUS
 
TYPE 1 DM
 
TYPE 2 DM
 
GDM(PREGNENCY)
 
COMPLICATIONS OF DM
 
 
 
 
 
 
 
ONLINE FORUMS
 
 
 
 
 
 
PROMINENT DIABETES CLINICS
 
 
 
 
 
 
PROMINENT ENDOCRINOLOGISTS
 
 
 
 
 
ENDOCRINOLOGIST (DIABETALOGIST) IN BANGALORE
 
Important Information about SITAGLIPTAN

SITAGLIPTAN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

SITAGLIPTAN should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

SITAGLIPTAN has not been studied in combination with insulin.

Selected Important Risk Information About SITAGLIPTAN

The recommended dose of SITAGLIPTAN is 100 mg once daily.

A dosage adjustment is recommended in patients with moderate or severe renal insufficiency or with end-stage renal disease requiring hemodialysis or peritoneal dialysis.

No dosage adjustment is required for patients with mild renal insufficiency. For patients with moderate renal insufficiency, the dose of SITAGLIPTAN is 50 mg once daily. For patients with severe renal insufficiency or with end-stage renal disease requiring hemodialysis or peritoneal dialysis, the dose of SITAGLIPTAN is 25 mg once daily.

SITAGLIPTAN is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.

As is typical with other antihyperglycemic agents used in combination with a sulfonylurea, when SITAGLIPTANwas used in combination with a sulfonylurea, a class of medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo. Therefore, a lower dose of sulfonylurea may be required to reduce the risk of hypoglycemia.

There have been postmarketing reports of serious hypersensitivity reactions in patients treated with SITAGLIPTAN, such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Onset of these reactions occurred within the first 3 months after initiation of treatment with SITAGLIPTAN, with some reports occurring after the first dose. If a hypersensitivity reaction is suspected, discontinue SITAGLIPTAN, assess for other potential causes for the event, and institute alternative treatment for diabetes.

In clinical studies, the adverse reactions reported, regardless of investigator assessment of causality, in >5% of patients treated with SITAGLIPTAN as monotherapy and in combination therapy and more commonly than in patients treated with placebo, were upper respiratory tract infection, nasopharyngitis, and headache.

The incidence of selected gastrointestinal adverse reactions in patients treated with SITAGLIPTAN100 mg vs placebo was as follows: abdominal pain (2.3%, 2.1%), nausea (1.4%, 0.6%), and diarrhea (3.0%, 2.3%).

USE IN SPECIFIC POPULATIONS

There are no adequate and well-controlled studies in pregnant women. Therefore, SITAGLIPTAN should be used during pregnancy only if clearly needed.

Merck & Co., Inc., maintains a registry to monitor the pregnancy outcomes of women exposed to SITAGLIPTANwhile pregnant. Health care providers are encouraged to report any prenatal exposure to SITAGLIPTANby calling the Pregnancy Registry at 1-800-986-8999.

It is not known whether sitagliptin is excreted in human milk. Therefore, caution should be exercised when SITAGLIPTANis administered to a nursing woman.

Safety and effectiveness of SITAGLIPTAN in children under 18 years have not been established.

No dosage adjustment is required based on age; however, because SITAGLIPTAN is substantially excreted by the kidney, it may be useful to assess renal function in elderly patients before initiation and periodically thereafter.

 
 
 
 
PRACTICAL CORNER
 
 
DKA
 
HONK
 
 
WISDOM CORNER
 
PITFALLS
 
GET INSPIRED
 
CONTROVERSIES
 
 
 
FOR HEALTHCARE PROFESSIONALS
 
 
 
 
RELIGIOUS BELIEF

 
SWINE FLU
 
 
 
 
 COPYRIGHT© 2009 E DIABETES MELLITUS.COM
 
 
 
 
DR. PRAVEEN .R  
 
 
ediabetesmellitus@gmail.com, ediabetesmellitus@rediffmail.com.